I couldn’t resist. Read the following paragraph, faithfully copied from CNN:
Vertex (down $1.06 to $35.71, Charts), a biotech based in Cambridge, Mass., is experimenting with a potential blockbuster hepatitis C treatment called VX-950. If tests are successful, the drug could enter the American market by 2009, reaching peak U.S. annual sales of $3 billion by 2013, said Ding Ding, analyst for Maxim Group.
Can you imagine going through life with a handle that basically everyone finds funny?